Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: Report from the SENTRY Antimicrobial Surveillance Program (2008-2009)

Diagnostic Microbiology and Infectious Disease

Volumn 68, Issue 3, 2010, Pages 278-283

  Pfaller, Michael A ^a   Castanheira, Mariana ^a   Messer, Shawn A ^a   Moet, Gary J ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungal resistance; Bloodstream infections; Candida; SENTRY Program

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ADULT; AGE DISTRIBUTION; AGED; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; CANDIDA; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA HAEMULONII; CANDIDA INCONSPICUA; CANDIDA KRUSEI; CANDIDA LAMBICA; CANDIDA NORVEGENSIS; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA SAKE; CANDIDA TROPICALIS; CONTROLLED STUDY; FUNGAL STRAIN; FUNGUS ISOLATION; HUMAN; INFANT; KLUYVEROMYCES MARXIANUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA ANOMALA; PICHIA GUILLIERMONDII; PICHIA JADINII; PRIORITY JOURNAL; YARROWIA LIPOLYTICA;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, FUNGAL; FEMALE; FUNGEMIA; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; YOUNG ADULT;

EID: 77957898661     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.06.015     Document Type: Article

References (41)

1. Ahlquist A., Farley M.M., Harrison L.H., Baughman W, Siegel B., Hollick R., Lockhart S.R., Magill S.S., Chiller T. Epidemiology of candidemia in metropolitan Atlanta and Baltimore City and County: prelilminary results of population-based active, laboratory surveillance-2008-2009 2009.
2. Alexander B.D., Schell W.A., Miller J.L., Long G.D., Perfect J.R. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 2005, 80:868-871.
3. Arendrup M.C., Fuursted K., Garn-Hansen B., Schonheyder H.C., Knudsen J.D., Jensen I.M., Bruun B., Christensen J.J., Johansen H.K. Semi-national surveillance of fungaemia in Denmark 2004-2006: increaseing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin. Microbiol. Infect. 2008, 14:487-494.
4. Chapeland-Leclerc F., Hennequin C., Papon N., Noel T., Girard A., Socie G., Ribaud P., Lacroix C. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob. Agents Chemother. 2010, 54:1360-1362.
5. Cleary J.D., Garcia-Effron G., Chapman S.W., Perlin D.S. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob. Agents Chemother. 2008, 52:2263-2265.
6. Clinical and Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing of yeasts (M27-A3) 2008, CLSI, Wayne, PA. 3rd ed.
7. Clinical and Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing of yeasts: 3rd informational supplement (M27-S3) 2008, CLSI, Wayne, PA.
8. Dodgson K.J., Dodgson A.R., Pujol D., Messer S.A., Soll D.R., Pfaller M.A. Caspofungin resistant C. glabrata. Clin. Microbiol. Infect. 2005, 11:364.
9. Falagas M.E., Apostolou K.E., Pappas V.D. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Clin Infect Dis 2006, 42:938-944.
10. Forrest G.N., Weekes E., Johnson J.K. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J. Infect. 2008, 56:126-129.
11. Garey K.W., Rege M., Pai M.P., Mingo D.E., Suda K.J., Turpin R.S., Bearden D.T. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43:25-31.
12. Kabbara N., Lacroix C., Peffault de Latour R., Socie G., Ghannoum M., Ribaud P. Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. Haematologica 2008, 93:639-640.
13. Kauffman C.A. Fungal infections in older adults. Clin. Infect. Dis. 2001, 33:550-555.
14. Krogh-Madsen M., Arendrup M.C., Heslet L., Knudsen J.D. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 2006, 42:938-944.
15. Labelle A.J., Micek S.T., Roubinian N., Kollef M.H. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit. Care Med. 2008, 36:2967-2972.
16. Malani A., Hmoud J., Chiu L., Carver P.L., Bielaczyc A., Kauffman C.A. Candida glabrata fungemia: experience in a tertiary care center. Clin. Infect. Dis. 2005, 41:975-981.
17. Morrell M., Fraser V.J., Kollef M.H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 2005, 49:3640-3645.
18. Pagano L., Fianchi L., Fanci R., Candoni A., Caira M., Posteraro B., Morselli M., Valentini C.G., Farina G., Mitra M.E., Offidani M., Sanguinetti M., Tosti M.E., Nosari A., Leone G., Viale P. Caspofungin for the treatment of candidaemia in patients with haematological malignancies. Clin. Microbiol. Infect. 2010, 16:298-301.
19. Panizo M.M., Reviakina V., Dolande M., Selgrad S. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains. Med. Mycol. 2009, 47:137-143.
20. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., Filler S.G., Fisher J.F., Kullberg B.J., Ostrosky-Zeichner L., Reboli A.C., Rex J.H., Walsh T.J., Sobel J.D. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2009, 48:503-535.
21. Parkins M.D., Sabuda D.M., Elsayed S., Laupland K.B. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J. Antimicrob. Chemother. 2007, 60:613-618.
22. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 2007, 20:133-163.
23. Pfaller M.A., Diekema D.J. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 2010, 36:1-53.
24. Pfaller M.A., Diekema D.J., Jones R.N., Messer S.A., Hollis R.J. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J. Clin. Microbiol. 2002, 40:852-856.
25. Pfaller M.A., Diekema D.J., Rex J.H., Espinel-Ingroff A., Johnson E.M., Andes D., Chaturvedi V., Ghannoum M.A., Odds F.C., Rinaldi M.G., Sheehan D.J., Troke P., Walsh T.J., Warnock D.W. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 2006, 44:819-826.
26. Pfaller M.A., Messer S.A., Hollis R.J., Boyken L., Tendolkar S., Kroeger J., Diekema D.J. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J. Clin. Microbiol. 2009, 47:3185-3190.
27. Pfaller M.A., Andes D., Diekema D.J., Espinel-Ingroff A., Sheehan D. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 2010, the CLSI Subcommittee for Antifungal Testing, in press.
28. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., Jones R.N., Turnidge J., Diekema D.J. Wild-type MIC distributions and epidemiological cutoff values (ECVs) for the echinocandins and Candida spp. J. Clin. Microbiol. 2010, 48:52-56.
29. Pfaller M.A., Diekema D.J., Andes D., Arendrup M.C., Brown S.D., Motyl M., Perlin D.S. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 2010, the CLSI Subcommittee for Antifungal Testing, in press.
30. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Ellis D., Tullio V., Rodloff A., Fu W., Ling T.A. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J. Clin. Microbiol. 2010, 48:1366-1377.
31. Pfeiffer C.D., Garcia-Effron G., Zaas A.K., Perfect J.R., Perlin D.S., Alexander B.D. Breakthrough invasive candidiasis on micafungin. J. Clin. Microbiol. 2010, 48:2373-2380.
32. Pound M.W., Townsend M.L., Drew R.H. Echinocandin pharmacodynamics: review and clinical implications. J. Antimicrob. Chemother. 2010, 65:1108-1118.
33. Sandven P., Bevanger L., Digranes A., Haukland H.H., Mannsaker T., Gaustad P. Candidemia in Norway (1991 to 2003): results from a nationwide study. J. Clin. Microbiol. 2006, 44:1977-1981.
34. Sendid B., Cotteau A., Francois N., D'Haveloose A., Standaert A., Camus D., Poulain D. Candidaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links. BMC Infect. Dis. 2006, 6:80.
35. Sipsas N.V., Lewis R.E., Tarrand J., Hachem R., Rolston K.V., Raad I.I., Kontoyiannis D.P. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009, 115:4745-4752.
36. Slavin M.A., Sorrell T.C., Marriott D., Thursky K.A., Nguyen Q., Ellis D.H., Morrissey C.O., Chen S.C. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J. Antimicrob. Chemother. 2010, 65:1042-1051.
37. Thompson G.R., Wiederhold N.P., Vallor A.C., Villareal N.C., Lewis J.S., Patterson T.F. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob. Agents Chemother. 2008, 52:3783-3785.
38. Tortorano A.M., Peman J., Bernhardt H., Klingspor L., Kibbler C.C., Faure O., Biraghi E., Canton E., Zimmermann K., Seaton S., Grillot R. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur. J. Clin. Microbiol. Infect. Dis. 2004, 23:317-322.
39. Turnidge J., Paterson D.L. Setting and revising antibacterial susceptibility breakpoints. Clin. Microbiol. Rev. 2007, 20:391-408.
40. Zaoutis T.E., Argon J., Chu J., Berlin J.A., Walsh T.J., Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin. Infect. Dis. 2005, 41:1232-1239.
41. Zilberberg M.D., Shorr A.F., Kollef M.H. Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect. Control Hosp. Epidemiol. 2008, 29:978-980.